Epilepsy and pregnancy

Neurology and Pregnancy: Clinical Management

Volumn , Issue , 2012, Pages 94-120

  Nashef, Lina A M ^a   Moran, Nicholas ^a   Lailey, Sara ^a   Richardson, Mark P ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904389770     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14988     Document Type: Chapter

References (139)

1. Herzog A. Disorders of reproduction in patients with epilepsy: Primary neurological mechanisms. Seizure 2008; 17(2): 101-110.
2. Isojärvi J. Disorders of reproduction in patients with epilepsy: Antiepileptic drug related mechanisms. Seizure 2008; 17(2): 111-119.
3. Taubøll E, Røste LS, Svalheim S, et al. Disorders of reproduction in epilepsy-what can we learn from animal studies? Seizure 2008; 17(2): 120-126.
4. Sukumaran SC, Sarma PS, Thomas SV. Polytherapy increases the risk of infertility in women with epilepsy. Neurology 2010; 75(15): 1351-1355.
5. Kariuki JG, Joshi MD, Adam AM, et al. Fertility rate of epileptic women at Kenyatta National Hospital. East Afr Med J 2008; 85 (7): 341-346.
6. Löfgren E, Pouta A, von Wendt L, et al. Epilepsy in the northern Finland birth cohort 1966 with special reference to fertility. Epilepsy Behav 2009; 14(1): 102-107.
7. Artama M, Isojärvi JI, Raitanen J, et al. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004; 159(11): 1057-1063.
8. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352(9145): 1970-1973.
9. Jalava M, Sillanpaa M. Reproductive activity and offspring health of young adults with childhood-onset epilepsy: a controlled study. Epilepsia 1997; 38(5): 532-540.
10. Webber MP, Hauser WA, Ottman R, et al. Fertility in persons with epilepsy. Epilepsia 1986; 27(6): 746-752.
11. Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia 1996; 9: 833-840.
12. Isojärvi J, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-1388.
13. Morrell MJ, Guldner GT. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64(2): 200-211.
14. Fairgrieve SD, Jackson M, Jonas P. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000; 321(7262): 674-675.
15. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998; 39(8): 887-892.
16. Seale CG, Morrell MJ, Nelson L, et al. Analysis of prenatal and gestational care given to women with epilepsy. Neurology 1998; 51(4): 1039-1045.
17. Viinikainen K, Eriksson K, Mönkkönen A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav 2006; 9(4): 636-640.
18. The Eurap Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66(3): 354-360.
19. Knight AH, Rhind EG, Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 1975; 16(1): 99-110.
20. Richmond JR, Krishnamoorthy P, Andermann E, et al. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004; 190(2): 371-379.
21. Vajda FJ, Hitchcock A, Graham J, et al. Seizure control in antiepileptic drug-treated pregnancy. Epilepsia 2008; 49(1): 172-176.
22. Harden CL, Hopp J, Ting TY, et al. Practice Parameter update: Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Neurology 2009; 73: 142-149.
23. Viinikainen K, Heinonen S, Eriksson K, et al. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006; 47 (1): 186-192.
24. Borthen I, Eide M, Daltveit AK, et al. Delivery outcome of women with epilepsy: a population-based cohort study. BJOG 2010; 117(12): 1537-1543.
25. Borthen I, Eide M, Daltveit AK, et al. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. BJOG 2011; 118(8): 956-965.
26. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006-08. BJOG 2011; 118(suppl 1): 1-203.
27. Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies-report of the ILAE Genetics Commission. Epilepsia 2010; 51(4): 655-670.
28. Berg AT, Berkovic S, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51(4): 676-685.
29. Sisodiya SM, Mefford, HC. Genetic contribution to common epilepsies. Curr Opin Neurol 2011; 24(2): 140-145.
30. Winawar MR, Shinnar SGH. Epidemiology of epilepsy or what do we tell families? Epilepsia 2005; 46(suppl 10): 24-30.
31. Doose H, Waltz S. Photosensitivity -genetics and clinical significance. Neuropediatrics 1993; 24(5): 249-255.
32. Waltz S, Stephani U. Inheritance of photosensitivity. Neuropediatrics 2000; 31(2): 82-85.
33. Tauer U, Lorenz, S, Lenzen, K, et al. Genetic dissection of photosensitivity and its relation to idiopathic generalized epilepsy. Ann Neurol 2005; 57(6): 866-873.
34. Vadlamudi L, Andermann E, Lombroso CT, et al. Epilepsy in twins: insights from unique historical data of William Lennox. Neurology 2004; 62: 1127-1133.
35. Berkovic SF, Howell RA, Hay DA, et al. Epilepsies in twins: genetics of the major epilepsy syndromes. Ann Neurol 1998; 43: 435-445.
36. Winawer MR, Marini C, Grinton BE, et al. Evidence for distinct genetic influences on generalized and localization related epilepsy. Epilepsia 2003; 44: 1176-1182.
37. Winawer MR, Rabinowitz D, Pedley TA, et al. Genetic influences on myoclonic and absence seizures. Neurology 2003; 61: 1576-1581.
38. Ottman R, Lee JH, Hauser WA, et al. Are generalized and localization-related epilepsies genetically distinct? Arch Neurol 1998; 55(3): 339-344.
39. Marini C, Scheffer IE, Crossland KM, et al. Genetic architecture of idiopathic generalized epilepsy: clinical genetic analysis of 55 multiplex families. Epilepsia 2004; 45: 467-s78.
40. Italian League Against Epilepsy Group. Concordance of clinical forms of epilepsy in families with several affected members. Epilepsia 1993; 34(5): 819-826.
41. Marini C, Harvey AS, Pelekanos JT, et al. Epilepsy in offspring of whom both parents have idiopathic generalized epilepsy: Biparental inheritance. Epilepsia 2003; 44(9): 1250-1254.
42. Jansen AC, Andermann E, and Andermann F. Biparental inheritance in idiopathic generalized epilepsy. Epilepsia 45(10): 1294-1295.
43. Doose H, Maurer A. Seizure risk in offspring of individuals with a history of febrile convulsions. Eur J Pediatr 1997; 156(6): 476-481.
44. Helbig KL, Bernhardt BA, Conway LJ, et al. Genetic risk perception and reproductive decision making among people with epilepsy. Epilepsia 2010; 51(9): 1874-1877.
45. Harden CL, Pennell PB, Koppel BS. Management issues for women with epilepsy -focus on pregnancy (an evidencebased review): II. Teratogenesis and perinatal outcomes. Epilepsia 2009; 50(5): 1237-1246.
46. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75(11): 1575-1583.
47. Nashef L, Walker W, Allen P, et al. Apnoea and bradycardia during epileptic seizures: relation to sudden death in epilepsy. J Neurol Neurosurg Psychiatry 1996; 60(3): 297-300.
48. Seyal M, Bateman LM, Albertson TE, et al. Respiratory changes with seizures in localization-related epilepsy: analysis of periictal hypercapnia and airflowpatterns. Epilepsia 2010; 51(8): 1359-1364.
49. Sahoo S, Klein P. Maternal complex partial seizure associated with fetal distress. Arch Neurol 2005; 62(8): 1304-1305.
50. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counselling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42(4): 149-160.
51. Tomson T, Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol 2005; 18(2): 135-140.
52. Holmes LB, Wyszynski DF, Lieberman ES. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61(5): 673-678.
53. Vajda FJ, O’Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: Results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11(8): 854-858.
54. Morrow J, Russell A, Gutherie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Neurol Neurosurg Psychiatry 2006; 77(2): 193-198.
55. Thomas SV, Ajaykuma B, Indhu K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 2008; 13(1): 229-236.
56. Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011;,76(21): 1817-1823.
57. Tomson T, Battino D, Craig J, et al; ILAE Commission on Therapeutic Strategies. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010; 51(5): 909-915.
58. Vajda FJ, Graham J, Hitchcock AA, et al. Foetal malformations after exposure to antiepileptic drugs in utero assessed at birth and 12 months later: observations from the Australian pregnancy register. Acta Neurol Scand 2011; 124(1): 9-12.
59. Wyszynski DF, Nambisan M, Surve T, et al. Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64(6): 961-965.
60. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis. Epilepsia 1997; 38(9): 981-990.
61. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10(7): 609-617; [Epub5 June 2011].
62. Holmes LB, Mittendorf R, Shen A, et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68(10): 1275-1281; [Epub 13 Jun 2011].
63. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70(22 pt 2): 2152-2158. Erratum in: Neurology 2009; 72(16): 1449.
64. Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia 2004; 45(11): 1465.
65. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305 (19): 1996-2002.
66. ten Berg K, Samren EB, van Oppen AC, et al. Levetiracetam use and pregnancy outcome. Reprod Toxicol 2005; 20(1): 175-178.
67. Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76(4): 383-389.
68. Hunt S, Russell A, Smithson WH, et al. UK Epilepsy and Pregnancy Register. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71(4): 272-276.
69. Ornoy A, Zvi N, Arnon J, et al. The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 2008; 25(3): 388-389.
70. Oyen N, Vollset SE, Eide MG, et al. Maternal epilepsy and offsprings’ adult intelligence: a population based study from Norway. Epilepsia 2007; 48(9): 1731-1738.
71. Finnell RH, Dansky LV. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: animal studies. Reprod Toxicol 1991; 5(4): 281-299.
72. Meador KJ, Zupanc ML. Neurodevelopmental outcomes of children born to mothers with epilepsy. Cleve Clin J Med 2004; 71(suppl 2): S38-S41.
73. Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39(4): 251-259.
74. Eriksson K, Viinikainen K, Monkkonen A, Aikia M, et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005; 65(3): 189-200.
75. Titze K, Koch S, Helge H, et al. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev Med Child Neurol 2008; 50(2): 117-122.
76. Koch S, Tize K, Zimmerman RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40(9): 1237-1243.
77. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2(7782): 839-843.
78. Gaily E, Kantola-Sorsa E, Granström ML. Specific cognitive dysfunction in children with epileptic mothers. Med Child Neurol 1990; 32(5): 403-414.
79. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274(19): 1518-1525.
80. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320(25): 1661-1666.
81. Skolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271(10): 767-770.
82. Wide K, Winbladh B, Tomson T, et al. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev Med Child Neurol 2000; 42(2): 87-92.
83. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Childhood 1996; 75: 517-520.
84. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62(1): 28-32.
85. Kantola-Sorsa E, Gaily E, Isoaho M, et al. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc 2007; 13(4): 642-652.
86. Vanoverloop D, Schnell RR, Harvey EA, et al. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992; 14(5): 329-335.
87. Holmes LB, Rosenberger PB, Harvey EA, et al. Intelligence and physical features of children of women with epilepsy. Teratology 2000; 61(3): 196-202.
88. Lösche G, Steinhausen H-C, Koch S, et al. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediat 1994; 83(9): 961-966.
89. Steinhausen HC, Lösche G, Koch S, et al. The psychological development of children of epileptic parents. I. Study design and comparative findings. Acta Paediatr 1994; 83(9): 955-960.
90. Hirano T, Fujioka K, Okada M, et al. Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia 2004; 45(suppl 8): 53-57.
91. Parisi P, Francia A, Vanacore N, et al. Psychomotor development and general movements in offspring of women with epilepsy and anticonvulsant therapy. Early Hum Dev 2003; 74(2): 97-108.
92. Hill RM, Verniaud WM, Horning MG, et al. Infant exposed in utero to antiepileptic drugs. A prospective study. Am J Dis Child 1974; 127: 645-653.
93. Nadebaum C, Anderson, VA, Vajda F, et al. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011; 76(8): 719-726.
94. Nadebaum C, Anderson VA, Vajda F, et al. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 2011; 17(1): 133-142.
95. Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011; 96(7): 643-647. [Epub 2011, Mar 17].
96. Meador KJ, Baker GA, Browning N, et al., NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities atthree years of age. Brain. 2011;134(Pt 2): 396-3404. [Epub 2011, Jan 11].
97. Meador KJ, Baker GA, Browning N, et al. Loring Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360(16): 1597-1605.
98. Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27(4): 993-1002.
99. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines fortherapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239-1276.
100. Harden CL, Hopp J, Ting TY, et al. American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency. Epilepsia 2009; 50(5): 1229-1236.
101. Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J 2009; 50(4): 517-520.
102. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46(9): 1414-1417.
103. Tomson, T. Gender aspects of pharmacokinetics therapeutic drug monitoring. Epilepsia 2005; 27: 718-721.
104. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a casereport. Epilepsia. 1997; 38(9): 1039-1041.
105. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000; 41(6): 709-713.
106. Pennell PB, Newport DJ, Stowe ZN, et al. Theimpact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004; 62(2): 292-295. Erratum in: Neurology 2010; 74(24): 2028.
107. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59(2): 251-255.
108. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: amonotherapy study. Neurology 2004; 63(3): 571-573.
109. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005; 65(3): 185-188.
110. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70(22 Pt 2): 2130-2136. [Epub 2007, Nov 28].
111. Ohman I, Beck O, Vitols S, et al. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008; 49(6): 1075-1080.
112. Franco V, Mazzucchelli I, Gatti G, et al. Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Ther Drug Monit 2008; 30(4): 544-547.
113. Fotopoulou C, Kretz R, Bauer S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res 2009; 85(1): 60-64.
114. Reimers A, Helde G, Bråthen G, et al. Lamotrigine and its N2-glucuronide during pregnancy: The significance of renal clearance and estradiol. Epilepsy Res 94(3): 198-205.
115. Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 67(7): 1297-1299.
116. Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009; 50 (9): 2163-2166.
117. Pennell PB, Peng L, Newport DJ. Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70(22 pt 2): 2130-2136.
118. Mazzucchelli I, Mazzucchelli I, Onat FY, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47(3): 504-509.
119. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67(8): 1497-1499.
120. Petrenaite V, Sabers A, Hansen-Schwartz J. Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Res 2009; 84(2-3): 245-249.
121. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007; 48(6): 1111-1116.
122. Westin AA, Reimers A, Helde G, et al. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008; 17(2): 192-198.
123. López-Fraile IP, Cid AO, Juste AO, et al. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: Clinical and outcome implications. Epilepsy Behav 2009; 15 (3): 372-375.
124. Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007; 48(6): 1111-1116. [Epub 2007, Mar 22].
125. Westin AA, Nakken, KO, Johannessen S, et al. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 2009; 50(3): 480-485.
126. Ohman I, Sabers A, de Flon P, et al. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res 2009; 87(2-3): 124-129.
127. Matar KM, Marafie NA. Effect of pregnancy on topiramate pharmacokinetics in rabbits. Xenobiotica 2011; 41(5): 416-421.
128. Winterbottom JB, Smyth RM, Jacoby A, et al. Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome. Cochrane Database Syst Rev 2008; (3): CD006645.
129. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Prognostic index for recurrence of seizures after remission of epilepsy. BMJ 1993; 306: 1374-1378.
130. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338(8760): 131-137.
131. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, et al. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010; (10): CD007950.
132. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: A prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009; 80(5): 506-511.
133. Choulika S, Grabowski E, Holmes LB. Is antenatal vitamin K prophylaxis needed for pregnant women taking anticonvulsants? Am J Obstet Gynecol 2004; 190(4): 882-883.
134. Kaaja E, Kaaja R, Matila R, et al. Enzyme-inducing antiepileptic drugsin pregnancy and the risk of bleeding in the neonate. Neurology 2002; 58(4): 549-553.
135. Crowther CA, Crosby DD, Henderson-Smart DJ. Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. Cochrane Database Syst Rev 2010; (1): CD000229.
136. Alarcon G, Nashef L, Cross H, et al. Oxford specialist handbooks in neurology: epilepsy. Oxford: Oxford University Press, 2009.
137. NICE, Department of Health, 2004. Available at: http://www.nice.org.uk.
138. Crawford P, Hudson S. Understanding the information needs of women with epilepsy at different lifestages: results of the ‘Ideal World’ survey. Seizure 2003; 12(7): 502-507.
139. BELL GS, Nashcf L, Kendall S, et al. Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Res 2002; 52: 139-146.